
Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
API, diagnostics, New Chemical Entity — Covid has thrown up new opportunities, and domestic pharma biggies are charging in with renewed focus.
In the coming year, the pharma industry will continue to reimagine itself while driving growth and boosting value.
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Restructuring to simplify corporate structure, create two separate listed entities.
In the latest episode of Biz Buzz, Umang Vohra, global MD & CEO, Cipla, talks about the paradigm shift in the Indian pharma industry, and Cipla's plans for booster shots of Covid-19 vaccine.
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
The production-linked incentive schemes seek to reimagine the dreams of the Indian economy. It will, of course, take a few years to completely evaluate the impact of them.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.